IRIS Institutional Research Information System - OPENBS Open Archive UniBS

POLVERELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.239
AS - Asia 3.085
EU - Europa 2.166
SA - Sud America 802
AF - Africa 88
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.387
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.134
SG - Singapore 1.295
CN - Cina 690
BR - Brasile 684
IT - Italia 554
HK - Hong Kong 467
DE - Germania 338
UA - Ucraina 214
FI - Finlandia 204
VN - Vietnam 200
PL - Polonia 181
TR - Turchia 156
RU - Federazione Russa 155
GB - Regno Unito 140
FR - Francia 85
IN - India 72
IE - Irlanda 71
CA - Canada 52
SE - Svezia 48
AR - Argentina 43
BD - Bangladesh 43
ZA - Sudafrica 41
CZ - Repubblica Ceca 40
MX - Messico 33
JP - Giappone 28
IQ - Iraq 27
NL - Olanda 27
AT - Austria 23
ES - Italia 22
BE - Belgio 17
EC - Ecuador 17
CO - Colombia 12
PY - Paraguay 12
JO - Giordania 11
ID - Indonesia 10
MA - Marocco 10
PE - Perù 10
TH - Thailandia 10
EG - Egitto 9
VE - Venezuela 9
IL - Israele 8
AE - Emirati Arabi Uniti 7
SA - Arabia Saudita 7
AZ - Azerbaigian 6
ET - Etiopia 6
LT - Lituania 6
TN - Tunisia 6
UY - Uruguay 6
UZ - Uzbekistan 6
CL - Cile 5
DZ - Algeria 5
GR - Grecia 5
IR - Iran 5
KE - Kenya 5
LV - Lettonia 5
MY - Malesia 5
PA - Panama 5
PS - Palestinian Territory 5
PT - Portogallo 5
AU - Australia 4
BG - Bulgaria 4
BO - Bolivia 4
HN - Honduras 4
JM - Giamaica 4
KG - Kirghizistan 4
LK - Sri Lanka 4
OM - Oman 4
CH - Svizzera 3
HU - Ungheria 3
PH - Filippine 3
PK - Pakistan 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EU - Europa 2
GA - Gabon 2
HR - Croazia 2
IM - Isola di Man 2
KR - Corea 2
MD - Moldavia 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
DK - Danimarca 1
EE - Estonia 1
GE - Georgia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MT - Malta 1
MU - Mauritius 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SY - Repubblica araba siriana 1
Totale 10.387
Salva come PNG Salva come JPEG
Città #
Singapore 581
Hong Kong 467
Ashburn 438
Fairfield 376
Beijing 264
New York 201
Chandler 195
Woodbridge 194
Warsaw 170
Seattle 169
Munich 160
Jacksonville 159
Wilmington 143
Helsinki 142
Los Angeles 139
Cambridge 138
Brescia 123
Dallas 122
Ann Arbor 121
Houston 119
Istanbul 115
Princeton 115
Des Moines 79
Dublin 69
São Paulo 68
Ho Chi Minh City 64
Shanghai 63
Boardman 61
Moscow 59
Redondo Beach 57
Chicago 55
San Francisco 55
The Dalles 51
Buffalo 49
Turku 47
Hanoi 43
Romola 41
Santa Clara 34
London 33
Brno 30
Milan 29
Johannesburg 27
Tokyo 26
Nuremberg 25
Brooklyn 24
Atlanta 20
Belo Horizonte 19
Nanjing 19
Orem 19
Rio de Janeiro 19
San Diego 19
Frankfurt am Main 18
Montreal 18
Pune 18
Brussels 17
Charlotte 17
Denver 17
Jinan 17
Rome 16
Stockholm 16
Toronto 16
Boston 15
Brasília 14
Dearborn 13
Barlassina 12
Amman 11
Amsterdam 11
Curitiba 11
Florence 11
Guangzhou 11
Manchester 11
Poplar 11
Biên Hòa 10
Da Nang 10
Haiphong 10
Kyiv 10
Lappeenranta 10
Phoenix 10
Tianjin 10
Verona 10
Wroclaw 10
Ankara 9
Baghdad 9
Bosio 9
Kocaeli 9
Shenyang 9
Changsha 8
Chennai 8
Chiswick 8
Falkenstein 8
Genoa 8
Mexico City 8
Bergamo 7
Betim 7
Düsseldorf 7
Gorlago 7
Jiaxing 7
Nanchang 7
Newark 7
Salvador 7
Totale 6.395
Salva come PNG Salva come JPEG
Nome #
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 272
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 183
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 174
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 156
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 151
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 145
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 142
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 141
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 140
Advances in CMV Management: A Single Center Real-Life Experience 138
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 137
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 137
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 134
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 134
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 129
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 127
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 126
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 121
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 121
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 120
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 118
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 118
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 116
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 115
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 110
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 109
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 109
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 108
Safety and Efficacy of ATG-based GvHD prophylaxis in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome: a single center experience 105
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 105
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) 105
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 104
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 104
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 103
Allogeneic transplantation for patient with myelodisplastic sindromes: a single centre experience 102
Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion 102
EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO) 100
ANTI-CMV IMMUNOGLOBULINS IN ASSOCIATION WITH ANTI-CMV DRUGS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SUBMITTED TO ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTI-CENTRE RETROSPECTIVE EXPERIENCE 99
Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience 99
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 98
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 96
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 95
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 93
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 92
Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message? 92
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 91
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis 90
Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit 89
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 87
Incidence and Outcome of Bacterial Blood Stream Infections in Allotransplanted Patients: Rethinking the Role of Fluoroquinolone Prophylaxis 87
EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: A RETROSPECTIVE MULTICENTRIC ANALYSIS ON 94 PATIENTS. 87
Favourable/Intermediate ELN-Risk Acute Myeloid Leukemia to Transplant or Not to Transplant First-Line? 87
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2) 86
Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation 85
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT) 85
Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients 83
PS1540 MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT) 83
Pre-Emptive Donor Lymphocyte Infusion As Optimal Treatment for Relapsed Acute Myeloid Leukemias and Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation: Insights from a French-Italian Study on 134 Patients 82
dsDNA from extracellular vesicles (EVs) in adult AML 82
A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation 82
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients 81
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 80
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation 78
Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration 77
Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood? 77
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation 76
Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study 75
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report 73
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS 72
Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients 71
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 71
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 69
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 69
Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS‐Relapse Registry Study 66
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 65
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 63
Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-02124-y) 63
Association of essential thrombocythemia and non-Hodgkin lymphoma: A single-centre experience 62
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients 61
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study 61
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 59
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: Possible role of MPL polymorphisms 59
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party 58
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 57
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY 57
A case report of acute myeloid leukemia and neurofibromatosis 1 54
Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable? 53
Bleeding in essential thrombocythaemia: A retrospective analysis on 565 patients 51
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 51
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 50
Long-term follow-up of essential thrombocythemia in young adults: Treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients 49
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 49
JAK2V617F mutation in essential thrombocythemia: Correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 49
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 48
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 47
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 47
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 45
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study 44
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 43
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: An in vitro study 42
Totale 9.233
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.508
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.508
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021683 0 0 0 0 0 134 61 109 90 155 75 59
2021/2022559 48 33 18 42 18 45 27 49 30 87 33 129
2022/2023683 79 19 30 52 55 136 3 129 82 17 43 38
2023/20241.196 51 26 96 62 72 221 50 46 287 14 17 254
2024/20252.877 39 56 82 334 291 240 175 116 399 236 522 387
2025/20263.163 508 618 495 919 566 57 0 0 0 0 0 0
Totale 10.580